Other first-generation FLT3 inhibitors evaluated for pediatric AML treatment include Sunitinib (20), Lestaurtinib (NCT00469859), and Midostaurin (NCT00866281, NCT03591510). This evidence concerns the gene FLT3 and acute myeloid leukemia.